On 30 March, 2020, ANVISA approved a resolution aimed at accelerating the prior authorization and communication process for products used in advanced therapy. This decision seeks to incentivize and operationalize the research for new treatments to the new coronavirus. The provisions of RDC nº 363 allow for an earlier entry into force of provisions already present in a prior RDC nº 338.
This content is available only in Portuguese. Find out more here.
